Recent developments in prostate cancer treatment have highlighted advancements in managing hormone-sensitive prostate cancer (HSPC). Historically, androgen-deprivation therapy (ADT) has been the primary approach for treating HSPC. This method targets the tumor’s reliance on androgens for growth and survival. However, emerging research has revealed significant molecular and biological heterogeneity within HSPC, prompting a shift toward more tailored therapeutic strategies.
For decades, ADT served as the cornerstone of systemic therapy for HSPC patients. The treatment focused on reducing androgen levels to inhibit tumor progression. Recent studies have expanded understanding of the disease’s complexity, uncovering variations in tumor biology that influence treatment response. These findings suggest that personalized approaches may improve outcomes by addressing specific characteristics of individual cases rather than relying solely on traditional monotherapy methods. Researchers continue to explore how these insights can refine treatment protocols and enhance patient care in this evolving field.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: November 27, 2025
發佈留言